NEW YORK – China's National Medical Products Administration (NMPA) on Wednesday granted conditional approval for Astellas' gilteritinib (Xospata) to treat FLT3-mutated, relapsed or refractory acute myeloid leukemia.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.